Header Logo

Connection

MARIA REDONDO to Blood Glucose

Back to Details
This is a "connection" page, showing publications MARIA REDONDO has written about Blood Glucose.
MARIA REDONDO
Connection Strength
2.254
Blood Glucose
  1. Index60 as an additional diagnostic criterion for type 1 diabetes. Diabetologia. 2021 04; 64(4):836-844.
    View in: PubMed
    Score: 0.491
  2. Therapeutics in pediatric diabetes: insulin and non-insulin approaches. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol Res. 2012 Jan; 65(1):1-4.
    View in: PubMed
    Score: 0.256
  3. A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts. Diabetes Technol Ther. 2025 03; 27(3):179-186.
    View in: PubMed
    Score: 0.161
  4. Age and sex mark clinical differences in the presentation of pediatric type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2025 Jan 29; 38(1):22-28.
    View in: PubMed
    Score: 0.160
  5. Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 Diabetes. Pediatr Diabetes. 2024; 2024:8343868.
    View in: PubMed
    Score: 0.158
  6. Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals. J Clin Endocrinol Metab. 2024 Jul 12; 109(8):2116-2123.
    View in: PubMed
    Score: 0.156
  7. Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies. Diabetes Care. 2023 05 01; 46(5):1098-1105.
    View in: PubMed
    Score: 0.144
  8. The Evolution of Hemoglobin A1c Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence. Diabetes Care. 2021 02; 44(2):301-312.
    View in: PubMed
    Score: 0.122
  9. GLP-1 Receptor Agonist as Adjuvant Therapy in Type 1 Diabetes: No Apparent Benefit for Beta-Cell Function or Glycemia. J Clin Endocrinol Metab. 2020 08 01; 105(8).
    View in: PubMed
    Score: 0.119
  10. Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes. Pediatr Diabetes. 2012 Nov; 13(7):564-71.
    View in: PubMed
    Score: 0.067
  11. Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval. Diabetes. 2025 Nov 01; 74(11):2101-2110.
    View in: PubMed
    Score: 0.043
  12. The Disposition Index in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes. Diabetes. 2025 Jul 01; 74(7):1196-1204.
    View in: PubMed
    Score: 0.042
  13. Metabolic, genetic and immunological features of relatives of type 1 diabetes patients with elevated insulin resistance. J Endocrinol Invest. 2025 Mar; 48(3):765-775.
    View in: PubMed
    Score: 0.040
  14. Identification of type 1 diabetes risk phenotypes using an outcome-guided clustering analysis. Diabetologia. 2024 Nov; 67(11):2507-2517.
    View in: PubMed
    Score: 0.039
  15. Persistence of ?-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening. Diabetes Care. 2022 12 01; 45(12):2982-2990.
    View in: PubMed
    Score: 0.035
  16. The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk. Diabetes Care. 2022 10 01; 45(10):2264-2270.
    View in: PubMed
    Score: 0.034
  17. Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes. Diabetes Care. 2022 02 01; 45(2):311-318.
    View in: PubMed
    Score: 0.033
  18. Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts. Diabetes Care. 2021 10; 44(10):2329-2336.
    View in: PubMed
    Score: 0.032
  19. Early and late C-peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibody-positive individuals. Diabetes Obes Metab. 2020 06; 22(6):997-1000.
    View in: PubMed
    Score: 0.029
  20. Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care. 2020 01; 43(1):5-12.
    View in: PubMed
    Score: 0.028
  21. Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes? J Clin Endocrinol Metab. 2017 08 01; 102(8):2873-2880.
    View in: PubMed
    Score: 0.024
  22. Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study. Diabetes Care. 2016 Mar; 39(3):465-8.
    View in: PubMed
    Score: 0.022
  23. Race, socioeconomic status, and treatment center are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes. Diabetes Technol Ther. 2013 Nov; 15(11):929-34.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.